Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial
Authors' conclusion
Our findings highlight the variable risk of in-stent restenosis governed by relatively few patient and lesion factors and underscore the significance of optimal lesion preparation before drug-coated balloon therapy as a potentially modifiable factor.
Study context
- Population
- Patients with in-stent restenosis randomized to treatment with the paclitaxel-coated balloonrandomized to paclitaxel-coated balloon, of 600 patients with in-stent restenosis in the AGENT IDE trial
- Participants
- 406 patients
- Comparison
- Demographic, clinical, and core laboratory angiographic predictors of 2-year target lesion failure (TLF)
Methodological detailsCox proportional hazards model
- Cox proportional hazards model
Primary result
As reported in the abstract
2-year TLF (ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death) · 2-year follow-up
TLF occurred
106
27.0%
Further findings
Independent risk factors for 2-year TLF
| Comparison | Hazard ratio (95% CI) | |
|---|---|---|
| Multiple stent layers | 1.80 (1.23–2.65) | |
| White race | 1.71 (1.03–2.85) | |
| Target lesion in the left anterior descending artery · associated with a reduced risk of 2-year TLF | 0.56 (0.36–0.87) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Hazard ratio (per 10% increment) (95% CI) | |
|---|---|---|
| Independent risk factors for 2-year TLF — postlesion preparation in-lesion % diameter stenosis | 1.16 (1.03–1.31) | |
| 0.512Hazard ratio (log scale) |
Original publication
Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial. Circ Cardiovasc Interv. Published 6 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it